Skip to main content
Article thumbnail
Location of Repository

the European Medicines Agency (EMEA). The EMEA Committee for Medicinal Products for Human Use (CHMP)

By Andor W. J. M. Glaudemans, Alberto Signore, A. Signore, A. Signore, Medicina Nucleare and Ospedale S. Andrea

Abstract

# The Author(s) 2010. This article is published with open access at Springerlink.com “Caelum, non animum, mutant qui trans mare currunt” They change the sky, not their soul, who run across the sea. Horace, Epistles 1.11.27 In the wake of the United States ’ regulations on the use of 18 F-fluorodeoxyglucose (FDG), the Spanish medicines regulatory agency last year stated that the use of FDG with PET, although well established in the areas of cancer, cardiac medicine and neurology, is not yet sufficiently established, within the European Union, in the diagnosis of infectious and inflammatory diseases, and therefore should not be authorised as a diagnostic radiopharmaceutical in these conditions. This position was contested by other EU member states and the dispute was eventually referred t

Year: 2010
OAI identifier: oai:CiteSeerX.psu:10.1.1.351.9564
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://citeseerx.ist.psu.edu/v... (external link)
  • ftp://ftp.ncbi.nlm.nih.gov/pub... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.